EXLS
KURA
Early data, big smiles
Kura Oncology came out swinging with fresh results from its FIT-001 study, and the market’s reaction was basically: “Okay, now we’re listening.” The company said its darlifarnib-plus-cabozantinib combo posted a 44% overall response rate and a 94% disease control rate in patients with advanced clear cell renal cell carcinoma.
Why investors care
This isn’t just a science fair ribbon. The study is moving into Phase 1b dose expansion, which is the biotech equivalent of going from a promising garage band to the first real tour date. Kura is trying to pin down the best biologically active dose, and the early tumor-shrinkage signal — plus a manageable safety profile — gives the story some actual momentum.
The Exelixis cameo
Cabozantinib, the partner drug in the combo, is marketed by Exelixis as Cabometyx or Cometriq. So yes, EXLS gets a little ripple effect here too, though the headline belongs to Kura. In biotech land, one promising combo can turn two stocks into dinner-party conversation.
Big picture
The stock was up sharply in premarket trading, and for good reason: investors love a clean efficacy readout, especially in a hard-to-treat cancer setting. It’s still early innings, but Kura just gave the market a reason to keep the popcorn close.